

Available online at www.sciencedirect.com



Bioorganic & Medicinal Chemistry

Bioorganic & Medicinal Chemistry 14 (2006) 7967–7971

Carbocyclic pyrimidine nucleosides as inhibitors of S-adenosylhomocysteine hydrolase

Sylvester L. Mosley,^a Brian A. Bakke,^a Joshua M. Sadler,^a Naresh K. Sunkara,^a Kathleen M. Dorgan,^b Zhaohui Sunny Zhou^b and Katherine L. Seley-Radtke^{a,*}

^aDepartment of Chemistry and Biochemistry, University of Maryland, Baltimore County, 1000 Hilltop Circle, Baltimore, MD 21250, USA

^bDepartment of Chemistry, Washington State University, Pullman, WA 99164, USA

Received 15 March 2006; revised 14 July 2006; accepted 26 July 2006 Available online 10 August 2006

Abstract—The design, synthesis, and unexpected inhibitory activity against *S*-adenosyl-homocysteine (SAH) hydrolase (SAHase, EC 3.3.1.1) for a series of truncated carbocyclic pyrimidine nucleoside analogues is presented. Of the four nucleosides obtained, **10** was found to be active with a K_i value of 5.0 μ M against SAHase. © 2006 Elsevier Ltd. All rights reserved.

1. Introduction

The significant inhibitory activity exhibited by the carbocyclic nucleosides against S-adenosylhomocysteine hydrolase (SAHase) has, for the most part, been confined to adenosine analogues (Fig. 1).^{1–3} One notable exception⁴ was the unexpected inhibition exhibited by a split guanosine nucleoside 'fleximer.' However, to date, few non-adenosine analogues have been reported. Inhibition of SAHase and several other enzymes critical for viral replication has been suggested as strategic targets for the inhibition of the orthopox viruses.⁵ Given the lack of effective chemotherapeutics against the poxviruses and their potential for use in bioweapons, the search for new and potent inhibitors has increased in intensity.

It is well known that inhibition of SAHase also leads to inhibition of *S*-adenosyl-L-methionine (SAM) mediated biomethylations.¹ As a result, methylation reactions involved in viral replication become attractive targets for inhibition.⁶ Two of the first naturally occurring carbocyclic nucleosides to exhibit activity were aristeromycin (Ari, 1) and neplanocin A (NpcA, 3).^{7–9} Unfortunately their close resemblance to adenosine rendered them sus-

Keywords: Carbocyclic; Pyrimidine; Nucleoside; SAHase; MTAN.



Figure 1. Potent carbocyclic SAHase inhibitors.

ceptible to recognition and phosphorylation by cellular kinases, resulting in significant toxicity.¹⁰ In response to this, strategic removal of the 4'-hydroxymethyl group of Ari and NpcA to afford the 4',5'-saturated (2) and 4',5'-unsaturated (4) derivatives proved to be successful, as both were potent inhibitors of SAHase.^{11,12} Interestingly, neither served as a substrate for adenosine kinase or adenosine deaminase, thus did not exhibit the toxicity associated with Ari and NpcA.^{11,12}

Related to this, a report⁵ of potent activity by two carbocyclic pyrimidine nucleosides (Fig. 2) against cytidine triphosphate (CTP) synthetase, in addition to numerous substituted pyrimidines against thymidylate synthase, prompted us to consider the design and synthesis of additional carbocyclic pyrimidine analogues (Fig. 3), incorporating the truncated scaffold. In that regard, the first of the pyrimidine targets is described.

^{*} Corresponding author. Tel.: +1 410 455 8684; fax: +1 410 455 2608; e-mail: kseley@umbc.edu



Figure 2. Carbocyclic derivatives of uridine and cytidine.



Figure 3. Carbocyclic targets.

2. Chemistry

Traditional Mitsunobu coupling was envisioned as a logical route to realize the targets. The cyclopentenyl alcohol precursor^{13,14} was obtained in good yield, and, as shown in Scheme 1, coupled to N^3 -Bz-uracil. The benzoyl-protecting group was removed from the coupled product by stirring with a 1% NaOH solution in MeOH to afford analogue 13 in 45% yield for two steps. This precursor is extremely important to this synthesis because from it three different routes can be employed. The first included deprotection of analogue 13 with a mixture of TFA and H₂O to result in the first final target 9. Second, in order to get the next immediate target, analogue 13 was first reacted with TIPBSC1 then followed with mild ammonolysis conditions to give analogue 14 which was then deprotected in a similar fashion as with analogue 9 to give final target 10.

In order to synthesize the final two targets in this series, it was necessary to reduce the double bond of the cyclopentyl ring system and as a result analogue **13** was reduced



Scheme 1. Reagents and conditions: (a) i—N³-Bz-uracil, PPh₃, DIAD, CH₃CN, 0 °C to rt, 70%; ii—NaOH in MeOH (1%), rt, 15 h, 75%; (b) TFA/H₂O (2:1), rt, 3 h, 95%; (c) i—TIPBSCI, NEt₃, DMAP, CH₃CN, rt, 4 h; ii—NH₄OH, rt, 15 h, 65%.



Scheme 2. Reagents and conditions: (a) H_2 (25 psi), Pd/C, EtOH, rt, 30 min, quant.; (b) TFA/H₂O (2:1), rt, 3 h, 95%; (c) i—TIPBSCI, NEt₃, DMAP, CH₃CN, rt, 4 h; ii—NH₄OH, rt, 15 h, 65%.

using catalytic hydrogenation to give saturated cyclopentyl analogue **15** (Scheme 2). The isopropylidene group of analogue **15** was removed to give final target **11**. The oxo group of analogue **15** was also converted to amino **16**, which was then deprotected to give final target **12**.

The four targets were then screened for their ability to inhibit SAHase, DNA methyltransferase (MTase), and CTP synthetase. No activity was seen for any of the analogues against DNA methyltransferase or CTP synthetase (data not shown). For SAHase, in the first experiment the concentration of inhibitor was varied, while the concentration of substrate (SAH) was held constant at 10 µM. Conversion of SAH to adenosine and then to inosine was monitored at 265 nm (Fig. 4). In the second experiment, the concentration of inhibitor was held constant at 45 μ M, while the concentration of substrate was varied. Initial rates in the presence and absence of inhibitors were measured (Fig. 5). There was no change in absorbance at 265 nm in the absence of SAH. These experimental data best fit a competitive inhibition mechanism. The K_i value for compound 10 was found to be 5.0 \pm 0.9 μ M against SAHase in the hydrolysis direction, based on a K_m value of 7.9 μ M for the SAH substrate.¹⁵ Ongoing studies suggest that the mechanism may be more complicated than a simple competitive inhibition mechanism, so that the 'true' inhibitory form probably binds to the enzyme tighter than SAH. Detailed mechanistic studies will be reported in the future.

The four compounds were also screened for their ability to inhibit S-adenosylhomocysteine (SAH) nucleosidase



Figure 4. Inhibition of SAHase by 10. Assay solutions contained 50 mM potassium phosphate at pH 7.4, 0.39 units of adenosine deaminase, 132 nM of SAHase, $10 \,\mu$ M of SAH (substrate), and various concentrations of 10. Consumption of substrate was monitored at 265 nm.



Figure 5. Inhibition of SAHase by 10. In the assay solution, the concentration of 10 was held constant at $45 \,\mu$ M, while the concentration of substrate was varied. Rates in the presence (data points at bottom of plot) and absence (data points at top of plot) of inhibitors were measured.

(EC 3.2.2.9). SAH nucleosidase irreversibly cleaves SAH and 5'-methylthioadenosine (MTA) to form adenine and the analogous thioribose. This enzyme plays an important role in microbial pathways such as quorum sensing, biological methylation, polyamine synthesis, and methionine recycling. Inhibition of SAH nucleosidase has been shown to lead to a buildup of SAH and MTA, which are feedback inhibitors to various enzymes. This enzyme, encoded by the pfs gene, is presented in about half of all bacterial species, including Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, Streptococcus pneumoniae, Mycobacterium tuberculosis, Salmonella typhimurium, Haemophilus influenzae, Vibrio cholerae, and Bacillus anthracis; but is not found in mammals.^{16,17} Knockout of the *pfs* gene has been found to be lethal or to markedly impair cell growth. All together, SAH nucleosidase represents an attractive target for antimicrobial drug therapy. For SAH nucleosidase inhibition, concentration of inhibitor was varied, while the concentration of substrate (SAH) was held constant at 10.8 µM. Consumption of substrate was monitored at 265 nm. Compound 10 inhibited about 50% of the activity at approximately a 13-fold excess (data not shown). Given the limited structural similarity between the SAH substrate and compound 10, the finding was unexpected. Thus, in spite of its moderate inhibitory activity, compound **10** may serve as a lead compound for different approach to inhibit this nucleosidase.

3. Experimental

3.1. General

Melting points are uncorrected. ¹H and ¹³C spectra were operated at 300 and 75 MHz, respectively, all referenced to internal tetramethylsilane (TMS) at 0.0 ppm. The spin multiplicities are indicated by the symbols s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), and br (broad). Reactions were monitored by thin-layer chromatography (TLC) using 0.25 mm Whatman Diamond silica gel 60-F₂₅₄ precoated plates. Column chromatography was performed on Whatman silica, 200–400 mesh, 60 Å and elution with the indicated solvent system. Yields refer to chromatographically and spectroscopically (¹H and ¹³C NMR) homogeneous materials.

3.2. (1'S, 2'R, 3'S)-1-[(2',3'-O-Isopropylidene)-4'-cyclopenten-1'-yl]uracil (13)

To cyclopenten-ol (6.50 g, 41.67 mmol), N^3 -Bz-uracil (18.02 g, 83.33 mmol), and PPh₃ (21.88 g, 83.33 mmol) in anhydrous CH₃CN (500 mL) at 0 °C was added dropwise DIAD (16.85 g, 83.33 mmol, 16.52 mL). After stirring at rt for 15 h, the mixture was concentrated and purified by column chromatography (EtOAc/hexanes, 3:1) to afford 9.74 g of 3-benzoyl-1'-(2',2'-dimethyl-4',6'-dihydro-3'*H*-cyclopenta[1',3']dioxol-4'-yl)- 1*H*-pyrimidine-2,4-dione as a white solid. ¹H NMR (DMSOd₆): δ 1.23 (3H, s), 1.3 (3H, s), 4.71 (1H, d), 5.27 (1H, s), 5.29 (1H, d), 5.81 (1H, d), 5.84 (1H, dd), 6.23 (1H, dt), 4.71 (1H, d), 5.29 (2H, d), 5.84 (1H, dd), 5.85 (1H, d), 6.22 (1H, m), 7.51 (1H, d), 7.57 (2H, t), 7.78 (1H, t), 7.97 (2H, m). ¹³C NMR (DMSO-d₆): δ 24.4, 26.2, 69.1, 83.2, 84.6, 101.1, 111.8, 128.9, 129.0, 130.1, 131.6, 135.0, 139.0, 143.0, 149.9, 163.0, 168.8.

NaOH (10 mL, 1% in MeOH) was added to the coupled product and the mixture was allowed to stir at rt for 12 h. After this time, the mixture was neutralized with HCl (1 N), the solvent removed, and the resulting residue was dissolved in EtOAc (50 mL), washed with H₂O (25 mL), dried (MgSO₄), filtered, and concentrated to give a solid. This solid was purified by column chromatography (EtOAc/hexanes, 4:1) to afford **13** (7.50 g, 71%) as a white solid. ¹H NMR (DMSO-*d*₆): δ 1.22 (3H, s), 1.31, (3H, s), 4.53 (1H, d), 5.27 (2H, m), 5.52 (1H, dd), 5.77 (1H, dd), 6.19 (1H, d), 7.23 (1H, d), 11.31 (1H, s).¹³C NMR (CD₃OD): δ 24.4, 26.2, 68.4, 83.4, 84.6, 101.2, 111.7, 129.3, 138.5, 142.5, 151.3, 165.0. Anal. Calcd for C₁₂H₁₄N₂O₄: C, 57.59; H, 5.64; N, 11.19. Found: C, 57.92; H, 5.75; N, 11.18.

3.3. (1'S, 2'R,3'S)-1-[(2',3'-Dihydroxy)-4'-cyclopenten-1'-yl]uracil (9)

A mixture of 13 (0.15 g, 0.60 mmol) in TFA/H₂O (2:1, 4 mL) was allowed to stir for 12 h at rt upon which time

the TFA/H₂O was removed by evaporation. The resulting residue was coevaporated with MeOH (3×10 mL) to remove trace amounts of TFA. The resulting residue was then purified using C-18 HPLC eluting 90:10, H₂O/MeOH \rightarrow 50:50, H₂O/MeOH \rightarrow 10:90, H₂O/MeOH afford **9** (0.106 g, 83 %) as a white solid. ¹H NMR (CD₃OD): δ 4.10 (1H, t), 4.55–4.60 (1H, dd), 5.45–5.50 (1H, dd), 5.70 (1H, d), 5.90 (1H, d), 6.20–6.23 (1H, dd), 7.40 (1H, dd). ¹³C NMR (CD₃OD): δ 66.6, 73.0, 76.5, 101.6, 132.4, 136.7, 142.3, 151.8, 165.0. HRMS: calcd for C₉H₁₀N₂O₄ (M+H)⁺, 211.19; found, 211.07.

3.4. (1'*S*,2'*R*,3'*S*)-1-[(2',3'-*O*-Isopropylidene)-4'-cyclopenten-1'-yl]cytosine (14)

To a solution of 13 (0.75 g, 3.00 mmol), DMAP (1.47 g, 12.00 mmol), and Et₃N (20 mL) in anhydrous CH₃CN (100 mL) at 0 °C was added portionwise TIPBSC1 (3.63 g, 12.00 mmol). After stirring at rt for 3 h, NH₄OH (50 mL) was added and the mixture continued to stir for 12 h at rt. The solvent was then removed and the resulting residue was purified via column chromatography (EtOAc/acetone/EtOH/H2O, 6:1:1:0.5) to afford **14** (0.58 g, 78%) as a white solid. ¹H NMR (CD₃OD): δ 1.27 (3H, s) 1.38 (3H, s), 4.53-4.54 (1H, d), 5.32-5.34 (1H, m), 5.43 (1H, m), 5.76–5.78 (1H, m), 5.81–5.83 (1H, d), 6.19–6.21 (1H, m), 7.30–7.32 (1H, m). $^{13}\mathrm{C}$ NMR (CD₃OD): δ 24.6, 26.3, 69.3, 83.8, 84.7, 94.8, 111.54, 130, 138.1, 157.4, 142.8, 166.3. Anal. Calcd for C₁₂H₁₅N₃O₃(0.75 H₂O): C, 54.88; H, 6.33; N,16.00. Found: C, 54.64; H, 5.83; N, 15.73.

3.5. (1'*S*, 2'*R*,3'*S*)-1-[(2',3'-Dihydroxy)-4'-cyclopenten-1'-yl]cytosine (10)

See procedure for **9** for other reaction details. Compound **14** (0.15 g, 0.60 mmol) and TFA (4 mL) afforded **10** (0.11 g, 87%) as a white solid. ¹H NMR (CD₃OD): δ 4.03–4.05 (1H, t), 4.58–4.59 (1H, m), 5.47–5.50 (1H, m), 5.90–5.98 (2H, dd), 6.19–6.21 (1H, m), 7.55–7.56 (1H, d). ¹³C NMR (CD₃OD): δ 67.8, 73.7, 76.9, 95.1, 132.6, 136.4, 142.6, 157.9, 166.0. Anal. Calcd for C₉H₁₁N₃O₃: C, 51.67, H, 5.30, N, 20.09. Found: C, 51.78, H, 5.39, N, 19.70.

3.6. (1'*S*,2'*R*,3'*S*)-1-[2',3'-(*O*-Isopropylidene)-cyclopent-1'-yl]uracil (15)

To **13** (0.25 g, 1 mmol) in MeOH (10 mL) was added Pd/ C (10 mol %, 0.025 g). This mixture was hydrogenated at a pressure of 25 psi for 20 min. The Pd/C was removed by filtration and the filtrate was concentrated to afford 0.26 g of **15** in quantitative yield as a white solid. ¹H NMR (DMSO- d_6): δ 1.20 (3H, s), 1.35 (3H, s), 1.65–1.82 (2H, m), 1.95–2.15 (2H, m), 4.63 (1H, m), 4.64 (1H, m), 4.71 (1H, dd), 5.52 (1H, d), 7.58 (1H, d) and 11.26 (1H, s). ¹³C NMR (DMSO- d_6) δ 24.4, 27.3, 29.1, 31.2, 63.9, 80.3, 84.4, 101.8, 110.0, 143.9, 152.6, 163.8. Anal. Calcd for C₁₂H₁₆N₂O₄(0.25 H₂O): C, 56.30; H, 6.50; N, 10.95. Found: C, 56.42; H, 6.44; N,10.88.

3.7. (1'*S*,2'*R*,3'*S*)-1-[(2',3'-Dihydroxy)-cyclopent-1'yl]uracil (11)

See procedure for **9** for other reaction details. Compound **15** (0.25 g, 0.99 mmol) and TFA (15 mL) afforded **11** (0.19 g, 91%) as a white solid. ¹H NMR (CD₃OD): δ 1.69–1.79 (2H, m), 2.06–2.21 (2H, m), 4.06 (1H, m), 4.22–4.25 (1H, dd), 4.61–4.67 (1H, q), 4.86 (1H, s), 5.65–5.67 (1H, d), 7.62–7.64 (1H, d). ¹³C NMR (CD₃OD): δ 19.9, 26.2, 59.5, 77.2, 85.9, 102.4, 141.3, 150.9, 163.6. Anal. Calcd for C₉H₁₂N₂O₄ (0.6 H₂O): C, 48.49, H, 5.96, N, 12.57. Found: C, 48.79, H, 5.51, N, 12.20.

3.8. (1'*S*,2'*R*,3'*S*)-1-[(2',3'-*O*-Isopropylidene)-cyclopent-1'-yl]cytosine (16)

See procedure for **14** for reaction details. Compound **15** (0.42 g, 1.67 mmol), DMAP (0.81 g, 6.66 mmol), Et₃N (12 mL), and CH₃CN (75 mL) afforded **16** (0.34 g, 81%) as a white solid. ¹H NMR (DMSO- d_6): δ 1.18 (s, 3H), 1.36 (s, 3H), 1.64–1.80 (m, 2H), 1.94–2.15 (m, 2H), 4.40–4.50 (m, 1H), 4.60–4.68 (dd, 1H), 4.69 (m, 1H), 5.65 (d, 1H), 7.10 (br s, 1H), 7.30 (br s, 1H), 7.50 (d, 1H). ¹³C NMR (DMSO- d_6): δ 22.3, 23.8, 29.5, 30.5, 64.9, 80.6, 84.7, 110.7, 144.9, 163.0.

3.9. (1'*S*,2'*R*,3'*S*)-1-[(2',3'-Dihydroxy)-cyclopent-1'yl]cytosine (12)

See procedure for **9** for other reaction details. Compound **16** (0.10 g, 0.40 mmol) and TFA (5 mL) afforded **12** (0.07 g, 85%) as a white solid. ¹H NMR (DMSO-*d*₆): δ 1.4–1.6 (m, 2H), 1.8–2.1 (m, 2H), 3.85 (s, 1H), 4.05 (s, 1H), 4.3–4.6 (m, 2H), 4.61–4.8 (m, 1H), 5.65 (s, 1H), 6.95 (s, 2H), 7.55 (d, 1H). ¹³C NMR (DMSO-*d*₆): δ 39.4, 39.6, 63.1, 71.1, 75.5, 93.8, 144.7, 156.6, 165.8. Anal. Calcd for C₉H₁₃N₃O₃(0.5 H₂O): C, 49.08, H, 6.41, N, 19.08. Found: C, 49.21, H, 6.03, N, 18.73.

3.10. SAHase inhibition assay

A reported enzyme-coupled continuous assay in the hydrolysis direction was employed. In this assay, SAH is hydrolyzed to homocysteine and adenosine, which is subsequently converted by adenosine deaminase into ammonia and inosine, a process associated with an absorbance decrease around 265 nm.¹⁵ All assays were performed in thermostatted 1 cm quartz cuvettes at 37 °C maintained by a Peltier unit on a Cary 100 ultraviolet-visible photospectrometer. In a total volume of 928 µL, a typical enzyme assay solution contained 50 mM potassium phosphate at pH 7.4, 0.39 units of adenosine deaminase (Worthington Biochemical, catalog number LS009043), 132 nM of SAHase (final concentration; provided by Lynne Howell), 10 µM of SAH (final concentration), and various concentrations of inhibitors. The reactions were initiated by the addition of SAH. Under these conditions, SAH hydrolysis catalyzed by SAHase was rate limiting (data not shown). The kinetic data were analyzed using KaleidaGraph 4.0 (Synergy). Based on a competitive inhibition mechanism, the K_i value was deterusing the equation, $v = k_{cat} \times [S] \times [E]/$ mined $\{K_{\rm m} \times (1 + [I]/K_{\rm i}) + [S]\}; \text{ and } v, k_{\rm cat.} [S], [E], K_{\rm m}, [I], \text{ and}$ K_i stand for the initial reaction rates, rate constant, substrate concentration, enzyme concentration, Michaelis– Menten constant, inhibitor concentration, and dissociation constant of the enzyme–inhibitor complex, respectively. The K_m value for SAH in the hydrolysis direction was assumed to be 7.9 µM as previously reported.¹⁵

3.11. SAH nucleosidase assay

In this assay,¹⁸ SAH is hydrolyzed into S-ribosylhomocysteine and adenine, which is subsequently converted by adenine deaminase into ammonia and hypoxanthine, a process associated with a decrease in absorbance around 265 nm. Assays were performed in thermostatted 1-cm quartz cuvettes at 37 °C maintained by a Peltier unit on a Cary 100 ultraviolet-visible photospectrometer. In a total volume of 920 µL, a typical enzyme assay solution contained 50 mM KPi (pH 7.4), 100 µM MnSO₄, 30.0 nM adenine deaminase, 4.2 nM SAH nucleosidase, 10.8 uM SAH, and various concentrations of inhibitors. The reaction was initiated by the addition of SAH. Under the assay conditions, SAH hydrolysis catalyzed by the nucleosidase was rate limiting (data not shown). Manganese or other divalent ions (e.g., zinc) are required for adenine deaminase activity.^{19,20}

Acknowledgments

This work was supported by the National Cancer Institute (NCI/NIH RO1 CA 97634 to K.S.R.), the National Institute of Allergy and Infectious Diseases (NIAID/ NIH, 1R01AI058146 to Z.S.Z.), the National Institutes of Health/NIGMS Initiative for Minority Student Development (R25-GM55036 to S.L.M.), and the Herman Frasch Foundation (541-HF02 to Z.S.Z.). We are grateful to Prof. George Carmen of Rutgers University for the CTP synthetase assay, Prof. Moshe Szyf of McGill University for the DNA methyltransferase assays, and Prof. Lynne Howell of the hospital for Sick Children for providing the SAHase.

References and notes

- 1. De Clercq, E. Biochem. Pharmacol. 1987, 36, 2567-2575.
- De Clercq, E. Nucleosides Nucleotides 1994, 13, 1271– 1295.
- 3. De Clercq, E. Nucleosides Nucleotides 1998, 17, 625-634.
- Seley, K. L.; Quirk, S.; Salim, S.; Zhang, L.; Hagos, A. Bioorg. Med. Chem. Lett. 2003, 13, 1985–1988.
- 5. De Clercq, E. Clin. Microbiol. Rev. 2001, 14, 382-397.
- 6. Razin, A.; Szyf, M. Biochim. Biophys. Acta 1984, 782, 331-342.
- Yaginuma, S.; Muto, N.; Tsujino, M.; Sudate, Y.; Hayashi, M.; Otani, M. J. Antibiot. 1981, 34, 359–366.
- Hayashi, M.; Yaginuma, S.; Yoshioka, H.; Nakatsu, K. J. Antibiot. 1981, 34, 675–680.
- Kusaka, T.; Yamamoto, H.; Shibata, M.; Muroi, M.; Kishi, T.; Mizuno, K. J. Antibiot. 1968, 21, 255–263.
- Glazer, R. I.; Knode, M. C. J. Biol. Chem. 1984, 259, 12964–12969.
- Hasobe, M.; McKee, J. G.; Borcherding, D. R.; Borchardt, R. T. Antimicrob. Agents Chemother. 1987, 31, 1849–1851.
- Hasobe, M.; McKee, J. G.; Borcherding, D. R.; Keller, B. T.; Borchardt, R. T. *Mol. Pharmacol.* **1988**, *33*, 713– 720.
- Seley, K. L.; Schneller, S. W.; Rattendi, D.; Lane, S.; Bacchi, C. J. Antimicrob. Agents Chemother. 1997, 41, 1658–1661.
- Yang, M.; Ye, W.; Schneller, S. W. J. Org Chem. 2004, 69, 3993–3996.
- Elrod, P.; Zhang, J.; Yang, X.; Yin, D. H.; Hu, Y.; Borchardt, R. T.; Schowen, R. L. *Biochemistry* 2002, 41, 8134–8142.
- Lee, J. E.; Cornell, K. A.; Riscoe, M. K.; Howell, P. L. J. Biol. Chem. 2003, 278, 8761–8770.
- Lee, J. E.; Settembre, E. C.; Cornell, K. A.; Riscoe, M. K.; Sufrin, J. R.; Ealick, S. E.; Howell, P. L. *Biochemistry* 2004, 43, 5159–5169.
- Dorgan, K. M.; Wooderchak, W. L.; Wynn, D. P.; Karschner, E. L.; Alfaro, J. F.; Cui, Y.; Zhou, Z. S.; Hevel, J. M. Anal. Biochem. 2006, 350, 249–255.
- Matsui, H.; Shimaoka, M.; Kawasaki, H.; Takenaka, Y.; Kurahashi, O. *Biosci. Biotechnol. Biochem.* 2001, 65, 1112–1118.
- 20. Dorgan, K. M.; Zhou, Z. S. unpublished results.